Parexel Acquires Vitrana to Expand AI-Enabled Pharmacovigilance Capabilities

The acquisition integrates Vitrana’s system-agnostic platform into Parexel’s clinical development ecosystem, allowing compatibility with existing safety databases.

Parexel has acquired Vitrana, an AI-enabled pharmacovigilance (PV) technology provider, to expand its patient safety operations and create a unified model that combines safety services and technology under a single framework.

The acquisition integrates Vitrana’s system-agnostic platform into Parexel’s clinical development ecosystem, allowing compatibility with existing safety databases.

The platform is designed to support end-to-end pharmacovigilance processes, including electronic data capture (EDC) integration, serious adverse event (SAE) reconciliation, and digital adverse event reporting from patients.

With this move, Parexel aims to shift from a fragmented vendor model to a consolidated structure that allows clients to manage PV services and technology through a single provider. The approach is expected to reduce operational complexity and improve efficiency in safety monitoring across clinical development programs.

The combined system is intended to support faster data processing and improve first-time quality in safety reporting by automating routine pharmacovigilance tasks. This would allow safety teams to focus more on clinical interpretation and complex risk evaluation rather than manual data handling.

For clinical trial sites, the integration is expected to reduce duplicate data entry by improving connectivity between EDC systems and safety databases. This is also expected to support faster reconciliation of safety cases.

For patients, the platform introduces digital reporting options for adverse events, aimed at improving accessibility and timeliness of safety data submission. For sponsors, the integrated model simplifies oversight of pharmacovigilance workflows by consolidating technology and service delivery under one system.

According to Parexel leadership, the acquisition is intended to enhance operational efficiency and support compliance requirements across global clinical programs. Vitrana’s leadership stated that the partnership will enable broader deployment of its technology across international markets under Parexel’s global infrastructure.

Initially, Vitrana will operate as “Vitrana – a Parexel Company” while being integrated into Parexel’s Patient Safety Services organization.

Stay tuned for more such updates on Digital Health News